- IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer’s - POTOMAC, MD / ACCESS Newswire / March 26, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the ...
Explore IGC Pharma stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for IGC. IGC Pharma Revenue Declines 51% YoY Due To Completion Of Its Legacy Project In ...
Amid a market downturn, with the Nasdaq 100 now trading below its 200-day moving ... with a highway construction contract ...
IGC Pharma (IGC) announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitation in Alzheimer’s ...
The global sleep aid market is projected to surpass $100 billion by 2030, presenting, if verified through larger trials, a significant commercial opportunity for innovative therapies like IGC-AD1.
IGC Pharma (IGC) announced additional interim results from its ongoing Phase 2 clinical trial on IGC-AD1, an investigational treatment for ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer's - POTOMAC, MD / / March 26, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") ...
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback